Page last updated: 2024-12-05

nonoxynol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nonoxynol: Nonionic surfactant mixtures varying in the number of repeating ethoxy (oxy-1,2-ethanediyl) groups. They are used as detergents, emulsifiers, wetting agents, defoaming agents, etc. Nonoxynol-9, the compound with 9 repeating ethoxy groups, is a spermatocide, formulated primarily as a component of vaginal foams and creams. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7700
CHEMBL ID1797943
CHEBI ID53774
SCHEMBL ID198140
MeSH IDM0026036

Synonyms (43)

Synonym
nonoxinol
nonoxynol
nonoxynols
nonoxynol 10
26027-38-3
D06490
nonoxynol 15 (usan)
nonoxynol 4 (usan)
nonoxynol 9 (usp)
delfen (tn)
nonoxynol 30 (usan)
2-(4-nonylphenoxy)ethanol
2-(p-nonylphenoxy)ethanol
96827-63-3
ethylene glycol p-nonylphenyl ether
4-nonyl phenol monoethoxylate
4-nonylphenol monoethoxylate
CHEBI:53774
CHEMBL1797943
zmd36h3esx ,
ethanol, 2-(4-nonylphenoxy)-
unii-zmd36h3esx
104-35-8
127087-87-0
68131-40-8
FT-0673037
SCHEMBL198140
4-nonylphenol ethoxylate
DTXSID4058601
J-001157
AKOS026749958
4-nonylphenol-mono-ethoxylate
4-n-nonylphenol-mono-ethoxylate 10 microg/ml in methanol
4-n-nonylphenol-mono-ethoxylate
4-n-nonylphenol-mono-ethoxylate 10 microg/ml in acetone
(oxyeth-ylene) nonylphenyl ether
nonylphenol-1-ethoxylate
npeo1
KUXGUCNZFCVULO-UHFFFAOYSA-N
2-(4-nonylphenoxy)ethan-1-ol
4-nonyl phenol monoethoxylate-d4
F85204
ethanol, 2-(p-nonylphenoxy)-

Research Excerpts

Overview

Nonoxynol-9 (N-9) is a typical surfactant. It is a proved spermicide, but whether it is also a microbicide is uncertain.

ExcerptReferenceRelevance
"Nonoxynol-9 (N-9) is a typical surfactant. "( Update on nonoxynol-9 as vaginal spermicide.
Iyer, V; Poddar, SS, 2008
)
2.19
"Nonoxynol-9 (N-9) is a nonionic detergent and is the active component of many spermicidal preparations."( Lactobacillus species isolated from the vagina: identification, hydrogen peroxide production and nonoxynol-9 resistance.
Barberis, L; Daniele, MB; Pájaro, C; Pascual, LM, 2006
)
1.27
"Nonoxynol 9 is a proved spermicide, but whether it is also a microbicide is uncertain. "( A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases.
Roddy, RE; Ryan, KA; Tamoufé, U; Weir, SS; Wong, EL; Zekeng, L, 1998
)
2.06

Effects

Nonoxynol-9 (N-9) has been used worldwide as a spermicide to kill sperm for more than 60 years. Can cause side effects including vaginal irritation and can increase the rate of contraceptive failure.

ExcerptReferenceRelevance
"Nonoxynol-9 (N-9) has been used worldwide as a spermicide to kill sperm for more than 60 years but can cause side effects including vaginal irritation and can increase the rate of contraceptive failure. "( Effects of nonoxynol-9 (N-9) on sperm functions: systematic review and meta-analysis.
Chan, DYL; Chung, JPW; Lee, TL; Li, RHW; Li, TC; Lin, Z; Xu, M; Zhao, M, 2022
)
2.55
"Nonoxynol-9 has been suggested as a vaginal microbicide to protect against common sexually transmitted infections."( Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial.
Roddy, RE; Ryan, KA; Tamoufé, U; Tweedy, KG; Zekeng, L, 2002
)
2.16

Treatment

ExcerptReferenceRelevance
"Nonoxynol-9-treated mice were significantly more susceptible to challenge with a low dose of herpes simplex virus type 2; the response of PRO 2000-treated mice was similar to the response to placebo."( A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.
Galen, BT; Garin, A; Guzman, E; Hazrati, E; Herold, BC; Keller, MJ; Lira, SA; Martin, AP; Porter, DD; Wilson, SS, 2007
)
1.06

Toxicity

Nonoxynol-9 vaginal pessary was found to be safe and acceptable in once daily dose in low risk women after consecutive use for 14 days. In vitro experiments showed that nonoxynil-9 was highly toxic to human cervical and colon epithelial cells in a dose-dependent manner.

ExcerptReferenceRelevance
" According to Hodge and Sterne Chemical Substance Toxicity Classifications, the evaluated detergent was found to be a weakly toxic substance."( [Evaluation of general toxicity of detergent Rokafenol-8 and its effect on the aggressiveness of coal mine dust].
Olczyk, D; Szaflarska-Stojko, E; Szymczykiewicz, K, 1990
)
0.28
" This study indicates that the regular and proper use of OVT-n or OVT-m tablets are comparable and are a safe means of birth control."( A comparative study of the safety, effectiveness and acceptability of two foaming vaginal tablets (nonoxynol-9 versus menfegol) in Thai women.
Chompootaweep, S; Dusitsin, N, 1990
)
0.5
" Acute LD50 determinations in mice were also performed."( Comparison of the spermicidal activity and acute toxicity of nonoxynol-9 and agent 741 [alkylphenoxy polyethoxy ethanol(10)].
Chen, Q; Diao, XH; Kaminski, J; Waller, DP; Zaneveld, LJ, 1986
)
0.51
" However, the activity of N-9 is nonspecific, suggesting that virucidal levels may produce adverse effects including epithelial disruption, inflammation of the genital mucosa, or both."( Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
Flanagan, A; Kitchen, VS; Rosenstein, IJ; Smith, JR; Stafford, MK; Taylor-Robinson, D; Ward, H; Weber, J, 1998
)
0.65
"In vitro experiments showed that nonoxynol-9 was highly toxic to human cervical and colon epithelial cells in a dose-dependent manner."( Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9.
Beauchamp, D; Bergeron, MG; Cormier, H; Désormeaux, A; Gagné, N; Gourde, P; Juhász, J; Omar, RF; Rioux, JE; Tremblay, MJ, 1999
)
0.82
" Contraceptive efficacy was assessed by a pregnancy test, while safety was evaluated by performing gynecological examinations as well as reporting adverse events."( A multinational evaluation of the efficacy, safety and acceptability of the Protectaid contraceptive sponge.
Colin, P; Creatsas, G; Drouin, J; Guerrero, E; Guilbert, E; Lemieux, L; Serfaty, D; Suissa, S, 2001
)
0.31
" Finally, the safety profile was very good, with no clinically significant evidence of local or systemic adverse reactions."( A multinational evaluation of the efficacy, safety and acceptability of the Protectaid contraceptive sponge.
Colin, P; Creatsas, G; Drouin, J; Guerrero, E; Guilbert, E; Lemieux, L; Serfaty, D; Suissa, S, 2001
)
0.31
"The new Protectaid sponge is a safe and effective non-hormonal contraceptive method for women."( A multinational evaluation of the efficacy, safety and acceptability of the Protectaid contraceptive sponge.
Colin, P; Creatsas, G; Drouin, J; Guerrero, E; Guilbert, E; Lemieux, L; Serfaty, D; Suissa, S, 2001
)
0.31
"The toxic effects of two forms of the new vaginal contraceptive sponge, Protectaid, in the cervical and vaginal tissues were studied."( Safety and tolerability of the new contraceptive sponge Protectaid.
Colin, P; Creatsas, G; Elsheikh, A, 2002
)
0.31
" On clinical examination, three adverse events were reported of which one could have been product related."( Phase I safety & preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India.
Bentley, M; Bollinger, R; Ghate, M; Joglekar, N; Joshi, S; Mehendale, S; Risbud, A; Shepherd, M; Unni, J, 2003
)
0.58
"Nonoxynol-9 vaginal pessary was found to be safe and acceptable in once daily dose in low risk women after consecutive use for 14 days."( Phase I safety & preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India.
Bentley, M; Bollinger, R; Ghate, M; Joglekar, N; Joshi, S; Mehendale, S; Risbud, A; Shepherd, M; Unni, J, 2003
)
2.02
"ACIDFORM appears to be safe for clinical use once a day."( Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product.
Amaral, E; Faundes, A; Mauck, C; Perdigao, A; Souza, MH; Waller, D; Zaneveld, L, 2006
)
0.55
" Measured outcomes included pregnancy rates, continuation rates, adverse events, and acceptability."( Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial.
Archer, D; Barnhart, K; Blithe, D; Burke, AE; Carr, BR; Creinin, MD; Jensen, JT; Liu, J; Schlaff, W; Thomas, M; Walsh, TL; Wan, LS; Westhoff, C; Wu, H, 2010
)
0.6
" Two serious adverse events were deemed possibly related to study product and neither occurred in the C31G group."( Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial.
Archer, D; Barnhart, K; Blithe, D; Burke, AE; Carr, BR; Creinin, MD; Jensen, JT; Liu, J; Schlaff, W; Thomas, M; Walsh, TL; Wan, LS; Westhoff, C; Wu, H, 2010
)
0.6
"Developing effective and safe microbicides requires study procedures (e."( Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials.
Loza, M; Moench, T; Radecki Breitkopf, C; Rosenthal, SL; Stanberry, LR; Vincent, K, 2012
)
0.38
" Endpoints included immune biomarkers in cervicovaginal lavage (CVL) and endocervical cytobrushes, inflammatory infiltrates in vaginal biopsies, epithelial integrity by naked eye, colposcopy, and histology, CVL anti-HIV activity, vaginal microflora, pH, and adverse events."( Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure.
Archer, DF; Callahan, MM; Chandra, N; Creinin, MD; Dezzutti, CS; Doncel, GF; Fichorova, RN; Hillier, SL; Lai, JJ; Mauck, CK; Schwartz, JL; Weiner, DH, 2013
)
0.39
" We compared changes generated with N9 and BZK treatment to the changes generated in response to tenofovir gel, a candidate microbicide that holds promise as a safe and effective microbicide."( New candidate biomarkers in the female genital tract to evaluate microbicide toxicity.
D'Andrea, A; Fields, S; Fong, J; Mirsalis, J; Rasoul, B; Shew, K; Song, B; Works, MG; Yiu, Y, 2014
)
0.4
" The FDA-recommended rabbit vaginal irritation (RVI) model serves as a first line selection tool for vaginal products; however, for decades it has been limited to histopathology scoring, insufficient to select safe anti-HIV microbicides."( A quantitative multiplex nuclease protection assay reveals immunotoxicity gene expression profiles in the rabbit model for vaginal drug safety evaluation.
Chandra, N; Doncel, GF; Fichorova, RN; Mendonca, K; Murray, R; Yamamoto, HS, 2015
)
0.42
" There were two possibly product-related mild adverse events."( A phase I randomized postcoital testing and safety study of the Caya diaphragm used with 3% Nonoxynol-9 gel, ContraGel or no gel.
Brache, V; Cochon, L; Doncel, GF; Kimble, T; Linton, K; Littlefield, S; Mauck, CK; Schwartz, JL; Thurman, A, 2017
)
0.68
"This study supports that Caya with ContraGel is safe and functions as well as Caya with N-9 in preventing PMS from reaching midcycle cervical mucus."( A phase I randomized postcoital testing and safety study of the Caya diaphragm used with 3% Nonoxynol-9 gel, ContraGel or no gel.
Brache, V; Cochon, L; Doncel, GF; Kimble, T; Linton, K; Littlefield, S; Mauck, CK; Schwartz, JL; Thurman, A, 2017
)
0.68
"A single-size diaphragm used with a personal lubricant gel containing lactic acid appears to be safe and to function as well as the same diaphragm used with N-9 in preventing PMS from reaching midcycle cervical mucus."( A phase I randomized postcoital testing and safety study of the Caya diaphragm used with 3% Nonoxynol-9 gel, ContraGel or no gel.
Brache, V; Cochon, L; Doncel, GF; Kimble, T; Linton, K; Littlefield, S; Mauck, CK; Schwartz, JL; Thurman, A, 2017
)
0.68

Pharmacokinetics

ExcerptReferenceRelevance
" A detailed account of its pharmacokinetic profile using highly sensitive detection method has not been reported yet."( Quantitative determination of microbicidal spermicide 'nonoxynol-9' in rabbit plasma and vaginal fluid using LC-ESI-MS/MS: application to pharmacokinetic study.
Bala, V; Bhatta, RS; Chandasana, H; Chhonker, YS; Gupta, G; Kumar, L; Sharma, VL, 2014
)
0.65
"In minimal physiologically based pharmacokinetic (mPBPK) models, physiological (e."( Theoretical Examination Seeking Tangible Physical Meanings of Slopes and Intercepts of Plasma Concentration-Time Relationships in Minimal Physiologically Based Pharmacokinetic Models.
Jeong, YS; Jusko, WJ, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" 1 (JZ1) in combination with nonoxynol-9 (N-9) was examined in vitro."( Spermicidal effect of Jieze No. 1 in combination with nonoxynol-9 in vitro.
Chen, Z; Lu, F; Xu, L; Xu, P, 2005
)
0.87

Bioavailability

ExcerptReferenceRelevance
" Most steroids were readily absorbed and their bioavailability after intravaginal instillation was greater than after oral administration because of a reduced first-pass effect."( Absorption from the vagina.
Benziger, DP; Edelson, J, 1983
)
0.27
" The concentration of nonoxynol-9 that entered semen in vitro was greater than its ED100 and the bioavailability was confirmed by demonstration of the retention of spermicidal action."( Diffusion of nonoxynol-9 into human semen in vitro.
Bruce, JM; Chantler, E; Gwanmesia, IL, 1998
)
0.98
" The plasma levels after administration of NPE revealed a considerable amount of absorption of NPE into the circulation and the bioavailability after intravaginal administration was calculated to be 66% by comparison with that after intravenous administration."( [Absorption of a vaginal contraceptive, nonoxynol (polyoxyethylene nonylphenyl ether) and its metabolism to nonylphenol in female rabbits].
Iida, K; Minami, Y; Tajima, H, 2000
)
0.57

Dosage Studied

Addition of (+)-propranolol to nonoxynol-9 shifted the dose-response curve to the left of the curves for either component alone, and a surprising synergistic action was evident. The dosage corresponded to about 10 mg of nonoxyynol 9 for an ejaculate, while those of local contraceptives are usually 100 mg. At present, some beneficial effects have been found, but there are doubts about the safety of high-dose use.

ExcerptRelevanceReference
" Addition of (+)-propranolol to nonoxynol-9 shifted the dose-response curve to the left of the curves for either component alone, and a surprising synergistic action was evident."( Comparative effects of (+)-propranolol and nonoxynol-9 on human sperm motility in-vitro.
Curtis-Prior, PB; Gadd, AL, 1990
)
0.83
"5 mM (+)- propranolol to nonoxynol-9, the dose-response curve moved to the left of the curves for either (+)-propranolol and nonoxynol-9 alone."( Comparative effects of (+)-propranolol and nonoxynol-9 on human sperm motility in-vitro.
Curtis-Prior, PB; Gadd, AL, 1990
)
0.85
"03), with a significant dose-response relationship (P = ."( Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes.
Davies, KS; DeLong, ER; Rekart, ML; Sacks, SL; Sellers, PW; Stiver, HG; Varner, TL, 1990
)
0.49
" The dosage corresponded to about 10 mg of nonoxynol 9 for an ejaculate, while those of local contraceptives are usually 100 mg."( [Cytological study of the mode of contraceptive action of nonoxynol-9].
Gonzales, J; Parier, JL, 1986
)
0.78
" A dose-response relationship was not apparent, and there was no variation in response among sperm donors."( Scanning electron microscopy of human spermatozoa after incubation with the spermicide nonoxynol-9.
Hahn, DW; McGuire, JJ; Wilborn, WH, 1983
)
0.49
" The measurements of sperm motility obtained in this study can be combined with information about local nonoxynol-9 concentrations in mucus to infer the dose-response of nonoxynol-9 against sperm in mucus."( Alteration of human sperm kinematics in cervical mucus due to nonoxynol-9.
Dunmire, EN; Katz, DF, 1997
)
0.75
" The design and dosage used in preparing the tablet drug delivery system provide short- and long-term release of the spermicidal agents, which results in almost immediate and extended enhancement of their contraceptive properties."( Assessment of a tablet drug delivery system incorporating nonoxynol-9 coprecipitated with polyvinylpyrrolidone in preventing the onset of pregnancy in rabbits.
Correa, JR; Zarmakoupis-Zavos, PN; Zavos, PM, 1998
)
0.54
" The purpose of this study was to determine the dose-response effects of G-D, N9, EDTA and G-D + EDTA on sperm motion parameters and acrosome status."( Dose-response effects of gramicidin-D, EDTA, and nonoxynol-9 on sperm motion parameters and acrosome status.
Centola, GM, 1998
)
0.55
" This study utilized computer-assisted methods to investigate the dose-response effects of incubation with G-D, N-9, EDTA, and G-D plus EDTA on sperm motion parameters and acrosome status."( Dose-response effects of gramicidin-D, EDTA, and nonoxynol-9 on sperm motion parameters and acrosome status.
Centola, GM, 1998
)
0.55
" The effectiveness of vaginal spermicides depends on a number of factors including: 1) the spermicidal potency of the active ingredient, 2) the release of the active ingredient from the dosage forms, and 3) the physical properties of the formulation as a barrier to sperm penetation through the cervix."( In vitro testing for potency of various spermicidal agents.
Lee, HP, 1981
)
0.26
" At present, some beneficial effects of the contraceptive nonoxynol-9 have been found, but there are doubts about the safety of high-dose, high-frequency use of this product, and the correct dosage to protect from HIV is unknown."( Empowering women: from the N9 microbicide to the Dimba and Laobe of Senegal.
Dodd, R,
)
0.37
" Positrons react to the structural changes of amorphous polymers very sensitively, so the method can be recommended as useful means for stability tests during the development phase of dosage forms containing such excipients."( Tracking of the physical ageing of amorphous pharmaceutical polymeric excipients by positron annihilation spectroscopy.
Orbán, A; Süvegh, K; Zelkó, R, 2006
)
0.33
"00) following N-9 gel dosing and 20."( Feasibility of radiolabeled small molecule permeability as a quantitative measure of microbicide candidate toxicity.
Aung, WS; Bakshi, RP; Coleman, JS; Fuchs, E; Hendrix, CW; Marzinke, MA; Robinson, J; Spiegel, HML, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID602812Inhibition of Sarcoplasmic/endoplasmic reticulum calcium ATPase in rabbit hind leg tissue microsomes assessed as rate of NADH oxidation coupled to SERCA-catalyzed ATP hydrolysis by spectroscopic assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Discovery of novel SERCA inhibitors by virtual screening of a large compound library.
AID602814Inhibition of Sarcoplasmic/endoplasmic reticulum calcium ATPase in rabbit hind leg tissue microsomes assessed as inorganic phosphate release by malachite green dye based chromogenic assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Discovery of novel SERCA inhibitors by virtual screening of a large compound library.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (599)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990128 (21.37)18.7374
1990's199 (33.22)18.2507
2000's169 (28.21)29.6817
2010's51 (8.51)24.3611
2020's52 (8.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.31 (24.57)
Research Supply Index6.62 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index120.15 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (68.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials99 (15.16%)5.53%
Reviews35 (5.36%)6.00%
Case Studies15 (2.30%)4.05%
Observational2 (0.31%)0.25%
Other502 (76.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Postcoital Testing Study of the SILCS Diaphragm Used With 3% Nonoxynol-9 Gel, ContraGel, or No Gel [NCT02309554]Phase 127 participants (Actual)Interventional2014-12-31Completed
A Multicenter, Open-Label, Randomized Study of the Contraceptive Efficacy and Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel [NCT01306331]Phase 33,389 participants (Actual)Interventional2011-04-30Completed
Contraceptive Effectiveness and Safety Study of the SILCS Diaphragm: the Pivotal Study [NCT00578877]Phase 2/Phase 3450 participants (Actual)Interventional2008-01-31Completed
Characterization and Use of Urine Pregnanediol Rapid Test and Its Use for Confirming Ovulation - Proov (Ovulation Double Check) Test [NCT03924440]350 participants (Anticipated)Observational2016-10-01Enrolling by invitation
A Phase II/III Multicenter, Randomized, Double-masked, Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol® [NCT00274261]Phase 31,565 participants (Actual)Interventional2004-06-30Completed
A Parallel Group, Randomized, Open-label Study to Investigate the Effect of the Intravaginally Administered Antimycotic Miconazole, Antibiotic Clindamycin, Spermicide Nonoxynol-9, or Co-usage of Tampons on 3 Consecutive Days on the Pharmacokinetics of Ana [NCT02545452]Phase 152 participants (Actual)Interventional2015-09-15Completed
A Pilot Protocol to Determine the Effects of Chemical and Mechanical Stress on Rectal Permeability as a Surrogate for Toxicity Evaluation of Rectally Applied Microbicides [NCT00389311]Early Phase 112 participants (Actual)Interventional2007-04-30Completed
Effectiveness of BenZalkonium Chloride Gel as Vaginal Contraceptive: a Multicentric Randomized Controlled Trial [NCT00692952]Phase 2240 participants (Actual)Interventional2004-03-31Completed
Phase III Nonoxynol-9 and HIV Infection [NCT00000926]Phase 34,400 participants InterventionalCompleted
Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation [NCT01593124]Phase 220 participants (Actual)Interventional2012-05-31Completed
Phase I Rectal Microbicide Study [NCT00000929]Phase 170 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00274261 (2) [back to overview]Incidence of Adverse Events.
NCT00274261 (2) [back to overview]The Cumulative Probability of Typical-use 6 Month (183 Days) Pregnancy.
NCT00578877 (1) [back to overview]Percent Probability of Pregnancy Among Users of the SILCS Diaphragm Used With Contraceptive Gel Over 6 Months of Typical Use
NCT01306331 (2) [back to overview]6-Month (183 Days) Cumulative Pregnancy Percentage
NCT01306331 (2) [back to overview]6-Month (183 Days) Cumulative Pregnancy Percentage for Subjects With Perfect Use

Incidence of Adverse Events.

Evaluated by comparing the incidence of Adverse Events (AEs) among subjects using their assigned treatment for at least one day. (NCT00274261)
Timeframe: duration of the study - through 6 month or 12 months of use

InterventionParticipants (Count of Participants)
C31G Vaginal Gel617
Conceptrol® Vaginal Gel434

[back to top]

The Cumulative Probability of Typical-use 6 Month (183 Days) Pregnancy.

Number of pregnancies in women using C31G gel for 6 months (183 days) compared to women using Conceptrol gel for the same time frame. (NCT00274261)
Timeframe: 6 months

Intervention6 month probability of pregnancy (Number)
C31G0.12
Conceptrol0.12

[back to top]

Percent Probability of Pregnancy Among Users of the SILCS Diaphragm Used With Contraceptive Gel Over 6 Months of Typical Use

(NCT00578877)
Timeframe: 6 months

Interventionpercent probability (Number)
N-9 Gel With SILCS Diaphragm12.5
BufferGel With SILCS Diaphragm9.6

[back to top]

6-Month (183 Days) Cumulative Pregnancy Percentage

The primary endpoint was the evaluation of contraceptive efficacy over six months (183 days) of Amphora™ Gel use when compared to Conceptrol® Vaginal Gel. Kaplan-Meier methods were used to estimate the six-month cumulative pregnancy percentage of women in the MITT population by treatment group (NCT01306331)
Timeframe: 183 days

Interventionpregnancy percentage (Mean)
Conceptrol10.0
Amphora10.5

[back to top]

6-Month (183 Days) Cumulative Pregnancy Percentage for Subjects With Perfect Use

Perfect use contraceptive efficacy over six months (183 days) of Amphora™ Gel use when compared to Conceptrol® Vaginal Gel. Kaplan-Meier methods were used to estimate the six-month cumulative pregnancy percentage of women in the efficacy evaluable (EE) population by treatment group (NCT01306331)
Timeframe: 183 days

Interventionpregnancy percentage (Mean)
Conceptrol4.2
Amphora4.1

[back to top]